Based on the analysis of 16 randomized clinical trials (RCTs), researchers from China concluded that “anti-inflammatory therapies targeting pathogenic process of diabetes can significantly reduce the level of fasting glucose, HbA1c, and CRP in patients with diabetes” [115]. The gene discussed is CRP; the disease is diabetes mellitus.